knowledge -WSS

knowledge

author：explore 2025-09-06 09:10:26 - browse：72158

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Medicare Advantage coverage denials need scrutiny, senators say

explore

WSS

Ask STAT: What do you want to know about ChatGPT in medicine?

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Medicare Advantage coverage denials need scrutiny, senators say

With FDA staff opposed to Sarepta therapy, top official intervened

Weight bias in eating disorder treatment complicated by new weight loss drugs

With FDA staff opposed to Sarepta therapy, top official intervened

explore

knowledge

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Colonoscopy at 40? Study finds a possible benefit

Alkermes shareholders re

Why we need to separate burnout from moral injury in health care

Dobbs anniversary: the lost opportunity of abortion as health care

Ascension's ugly legal battle over care for poor patients in Texas

What does generative AI mean for health care? We asked experts

Cloning humans is technically possible. It's curious no one has tried

Dobbs anniversary: the lost opportunity of abortion as health care

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

Gene therapy denied for Afghan refugee whose father aided U.S.

A preacher's new calling: Diversifying neuroscience research

Death of patient in Alzheimer’s trial raises question of possible risks

Donald Trump's relentless attacks on special counsel Jack Smith

Merck to acquire Harpoon Therapeutics for $680 million

Profiling embryos to choose those with higher IQs is almost a reality

focus

explore

hotspot

hotspot